NorthStar Medical Radioisotopes and Bayer Establish Supply Agreement for Actinium-225 (Ac-225) Therapeutic Radioisotope
Wednesday, July 19, 2023
NorthStar Medical Radioisotopes, a global leader in the development, production, and commercialization of radiopharmaceuticals for therapeutic applications and medical imaging, has announced a supply agreement with Bayer for the therapeutic radioisotope actinium-225 (Ac-225). This agreement signifies that NorthStar will provide Bayer with non-carrier added (n.c.a.) Ac-225, which is known for its environmentally friendly properties.
Bayer plans to utilize NorthStar's Ac-225 in multiple radiopharmaceutical programs. Ac-225, an alpha-emitting radioisotope, has gained significant interest in clinical studies exploring radiopharmaceutical therapy (RPT). RPT involves combining specific molecules with therapeutic radioisotopes like Ac-225 to precisely target and deliver therapeutic radiation doses to cancer cells while minimizing damage to nearby healthy tissue due to the short range of alpha radiation.
NorthStar aims to become the primary commercial-scale producer of n.c.a. Ac-225, thereby advancing clinical research and commercial radiopharmaceutical products. Their production method involves utilizing electron accelerator technology, which ensures the production of n.c.a. Ac-225 free from long-lived radioactive contaminants and byproducts associated with other production methods. This approach addresses regulatory and waste management challenges faced by hospitals and healthcare systems.
The collaboration between NorthStar Medical Radioisotopes and Bayer aims to meet the increasing demand for Ac-225 and contribute to the development of therapeutic options in the field of radiopharmaceuticals.